Tag Archives: ML7710

Modulight Spotlights: LASER-SHARP RESEARCH – December 2022

December 28, 2022 by Modulight
No comments
   Modulight Spotlights: LASER-SHARP RESEARCH – December 2022 This month’s research spotlight goes to H. Wakiyama, H. Kobayashi, et al. at National Cancer Institute, USA. Their study, published in Cancer Immunology Research journal, looked into immunological mechanisms behind hyperprogressive disease. Immune checkpoint inhibitors, despite being a major success story in the field of cancer therapy, unfortunately lead to this rapid progression of cancer in some patients, for yet poorly understood reasons. To study this, the research team partially depleted cytotoxic T cells by photoimmunotherapy, using CD8-targeted Continue reading →

Protected: Fluorescence imaging & endoscopy for tumor visualization and diagnostics

July 6, 2022 by Modulight Content
No comments
There is no excerpt because this is a protected post.Introduction to fluorescence imaging Fluorescence is a phenomenon where substance that has absorbed certain wavelength of light emits it back at another wavelength. These substances are called fluorophores or fluorescent dyes. The emitted light has a longer wavelength than the absorbed one since some energy of the photon is lost in the process. The difference in wavelengths between absorbed and emitted light, called Stokes shift, allows very low background for fluorescence detection by separating it from the excitation light. The process of fluorescence generation is Continue reading →

Light-based enhancement of vaccination in humans

December 20, 2021 by Modulight Content
No comments
  Motivation Vaccines should activate all branches of immunity, including T cells and antibody responses, for generating a strong immune response. For therapeutic cancer vaccines, it is especially important to induce strong cytotoxic T-cell responses, since cytotoxic T-cells are the most potent immune cells for killing cancer cells. While cytotoxic T-cells can often be induced  with viral vector and nucleic acid-based vaccines, peptide-based vaccines often induce only weak cytotoxic T-cell responses . When peptide antigens are taken up into antigen presenting cells, they are generally Continue reading →Customer case PCI Biotech is a biopharmaceutical company located in Norway. They are developing a novel light-based technology called photochemical internalization (PCI) that has potential to enhance delivery and efficacy of many types of therapies, including certain chemotherapies, peptide vaccines, and nucleic acid therapies. It can also decrease side effects due to improved spatiotemporal control of the treatment. The technology is currently in a pivotal clinical study for the treatment of inoperable bile duct cancer where PCI with gemcitabine is combined with standard gemcitabine/cisplatin chemotherapy. Continue reading →

Optimizing photosensitizer administration for cancer therapy

December 11, 2021 by Modulight Content
No comments
  Motivation While Photofrin PDT is an approved oncological therapy for multiple indications, its wider use is hindered by prolonged skin photosensitivity lasting several weeks. The aim of this study is to investigate intratumoral Photofrin administration as a way to decrease skin photosensitivity compared to the standard IV injection protocol. Tumor necrosis after PDT was assessed with immunohistochemical staining and Photofrin distributions by fluorescence microscopy.       Results   Anti-tumor efficacy was similar between intratumoral and IV administration; however, smaller doses of Photofrin were Continue reading →Customer case University of Rochester belongs among the nation’s top research universities. Research at the Baran lab focuses on anti-microbial PDT and optical image processing. The aim is to develop methods for utilizing quantitative information from CT, MR and PET imaging for PDT treatment planning as well as in the search of new biomarkers and therapeutic targets. Modulight products: ML7710 (630 & 665 nm) Link to the study: Timothy M. Baran (Ph.D., PI) Laser use: Ongoing clinical Phase 1 safety & feasibility study for methylene Continue reading →

Optimized light delivery in pancreatic cancer

November 10, 2021 by Modulight Content
No comments
Motivation for the study Efficient light delivery to the whole tumor is one of the main aspects of phototherapy. The efficacy of phototherapy has been demonstrated for several cancers via superficial illumination. Interstitial illumination could enhance light delivery deeper inside the tumor and potentially result in more effective tumor eradication. Hence, the aim of this study is to compare if the therapeutic efficacy of phototherapy is dependent on the light delivery strategies.   Results Phototherapy (PT) with both superficial and interstitial illumination methods efficiently eradicated Continue reading →Customer case University of California at Irvine (UCI), founded in 1965, is a Top 10 public university in USA. It is recognized for cutting-edge and innovative scientific research. Modulight products: ML7710 (689 nm) Laser use: Targeted phototherapy studies with photo-immunoconjugates Link to the study: Nzola De Magalhães, Adjunct Assistant Professor   Motivation for the study Efficient light delivery to the whole tumor is one of the main aspects of phototherapy. The efficacy of phototherapy has been demonstrated for several cancers via superficial illumination. Interstitial illumination could Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – September 2021

October 1, 2021 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – September 2021 Laser-Sharp Research nomination goes to this month for Professor Kobayashi’s team and Dr. Noriko Sato’s team at National Cancer Institute, National Institute of Health, USA. Their research published in a prestigious Cancer Research journal showed that photoimmunotherapy can not only target tumor cells, but can also be harnessed to target body’s own tumor-promoting immune cells within the tumor. These special cells called intratumoral Tregs were selectively killed by photoimmunotherapy upon illumination with ML7710 laser, which led to activation Continue reading →

Light delivery optimization for H&N cancer treatment

August 30, 2021 by Modulight Content
No comments
Results Illumination with one fiber Some level of tissue heating was observed at all used light intensities. At lower intensities (60-100 mW/cm), less than 5% of the tumor was subjected to >60 ⁰C temperature, a point where irreversible thermal damage will immediately occur (photothermal ablation). At intensities of 150-200 mW/cm, 15-20% of the tumor was at >60 ⁰C temperature. At 400 mW/cm, which is FDA-recommended light irradiance for iPDT, a substantial portion of the tumor, up to 60%, was above 60 ⁰C.   Above figures Continue reading →Customer case Roswell Park Comprehensive Cancer Center was founded in 1898 as the first institute in the US devoted exclusively to cancer treatment and research. It is also the place where photodynamic therapy (PDT) was developed in the late 1970s by Thomas Dougherty. The PDT center at Roswell Park is a leader in the use of photodynamic therapy for treating different cancers. Research work includes treatment planning and light dosimetry for interstitial and intraoperative PDT to improve the quality of life and survival of cancer patients Continue reading →

Protected: In-vivo distribution and vascular & tumor responses

August 23, 2021 by Modulight Content
No comments
There is no excerpt because this is a protected post.Customer case Erasmus MC is the largest and one of the best University Medical Centers in Europe. Modulight products: ML7710 (689 nm) Laser use: Activation of antibody-IRDye700DX conjugates for photoimmunotherapy of cancer. Link to the study:   Dominic Robinson (PI)   Research Research centered on PDT encompasses 3 main themes: Understanding the mechanism of action/theoretical bases of PDT Developing technology for PDT dosimetry/treatment monitoring Receptor targeted PDT/PIT. Main indications of interest are dermatology, gastroenterology and H&N cancer. Most recently the group has investigated mechanisms & effectiveness Continue reading →

Protected: New approach for targeted PDT of glioblastoma

August 17, 2021 by Modulight Content
No comments
There is no excerpt because this is a protected post.Customer case Research in close collaboration with University Medical Center Utrecht, Erasmus Medical Center and Leiden University Medical Center. Research focused on the efficacy and mechanisms of targeted cancer photoimmunotherapy using nanobodies (antibody fragments). The advantage of nanobodies lies in the combination of their small molecular size, with high binding affinity for their targets, resulting to high accumulation at the tumor site, better tumor penetration and faster clearance from blood circulation. The aim is to target therapy to cancer cell-expressing antigens like EGFR (H&N cancer) Continue reading →

Vision-sparing targeted phototherapy for uveal melanoma

July 30, 2021 by Modulight Content
No comments
Preliminary investigation of AU-011     Related Modulight products and Services   Related Publications Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Rhonda C. Kines, Cynthia D. Thompson, Sean Spring, Zhenyu Li, Elisabet de los Pinos, Stephen Monks and John T. Schiller Cancer Immunology Research, 2021, 9 (6)   A Phase 1b/2 Open-label Clinical Trial to Evaluate the Safety and Efficacy of AU-011 for the Treatment of Choroidal Melanoma Prithvi Mruthyunjaya, Amy C. Schefler, Ivana K. Continue reading →Customer case Aura Biosciences, headquartered in Cambridge, MA, is developing a new class of photoactivated therapy for cancer patients together with National Cancer Institute, Emory Eye Center and Wills Eye Hospital. The therapy is based on virus-like conjugates and its primary indication is uveal melanoma. The goal is to eventually develop this technology for multiple cancer indications, such as non-muscle invasive bladder cancer (NMIBC), for which plans are underway to conduct a clinical trial. Dr. Carol Shields, MD – Aura Biosciences Dr. Rhonda Kines, PhD – Continue reading →